The new OncAlert agreements will further expand Vigilant Biosciences’ reach and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the diagnosis and treatment of oral cancer.

Vigilant Biosciences Inc., an innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced three exclusive multiyear distribution agreements for sales and marketing of its OncAlert Oral Cancer product line in Benelux (Belgium, Netherlands, Luxembourg), Italy, South Africa, Puerto Rico and the Caribbean.

The new distribution partners include Bio-Connect Diagnostics B.V. for the distribution of the OncAlert oral cancer product line to the dental and medical markets in Benelux; Lagitre S.R.L. for the distribution of the OncAlert Oral Cancer product line in Italy and South Africa; and Isla Lab Products for the distribution of the OncAlert Oral Cancer product line in Puerto Rico and the Caribbean. As part of the new multiyear deals the OncAlert Oral Cancer product line will be available to customers in these regions starting later this year.

Vigilant Biosciences has previously announced multiple distribution agreements throughout Europe, Africa and Asia/Pacific. The new agreements will further expand Vigilant Biosciences’ reach throughout Europe, Africa and Latin America and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the diagnosis and treatment of oral cancer.

“Oral cancer is a growing problem not only in our region but worldwide, particularly with the increase in HPV-related oral cancer,” said Anand Lachmansingh, general manager, Bio-Connect Diagnostics. “Having a simple, cost-effective, and non-invasive test can aid dental professionals and clinicians in detecting oral cancer earlier, which will help to improve outcomes from this disease.”

Source: Dentistry iQ